drotrecogin alfa (activated) - search results

European Union - English - EMA (European Medicines Agency)

xigris

eli lilly nederland b.v. - drotrecogin alfa (activated) - sepsis; multiple organ failure - antithrombotic agents - xigris is indicated for the treatment of adult patients with severe sepsis with multiple organ failure when added to best standard care. the use of xigris should be considered mainly in situations when therapy can be started within 24 hours after the onset of organ failure (for further information see section 5.1).

Canada - English - Health Canada

xigris (5mg/vial) powder for solution

eli lilly canada inc - drotrecogin alfa (activated) - powder for solution - 5mg - drotrecogin alfa (activated) 5mg - other miscellaneous therapeutic agents

Canada - English - Health Canada

xigris (20mg/vial) powder for solution

eli lilly canada inc - drotrecogin alfa (activated) - powder for solution - 20mg - drotrecogin alfa (activated) 20mg - other miscellaneous therapeutic agents

New Zealand - English - Medsafe (Medicines Safety Authority)

xigris

eli lilly and company (nz) limited - drotrecogin alfa (activated) 20mg ([recombinant human acitvated protein c (rhapc)]) - powder for infusion - 20 mg - active: drotrecogin alfa (activated) 20mg ([recombinant human acitvated protein c (rhapc)]) excipient: hydrochloric acid citrate buffer (containing citrate, citric acid, hcl, naoh) hydrochloric acid sodium chloride sodium hydroxide sucrose water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

xigris

eli lilly and company (nz) limited - drotrecogin alfa (activated) 5mg ([recombinant human acitvated protein c (rhapc)]) - powder for infusion - 5 mg - active: drotrecogin alfa (activated) 5mg ([recombinant human acitvated protein c (rhapc)]) excipient: hydrochloric acid citrate buffer (containing citrate, citric acid, hcl, naoh) hydrochloric acid sodium chloride sodium hydroxide sucrose water for injection